相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials
Kaatje Bollaerts et al.
CLINICAL INFECTIOUS DISEASES (2022)
Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
Donald Hurley et al.
CLINICAL INFECTIOUS DISEASES (2021)
Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era
Sara de Miguel et al.
CLINICAL INFECTIOUS DISEASES (2021)
Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study
Cornelis H. van Werkhoven et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia
Bradford D. Gessner et al.
EXPERT REVIEW OF VACCINES (2021)
A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥ 65 years of age with different prior pneumococcal vaccination
Kevin Cannon et al.
VACCINE (2021)
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Heather L. Sings et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
Maria Deloria Knoll et al.
MICROORGANISMS (2021)
Unraveling the Impact of Pneumococcal Conjugate Vaccines on Ambulatory Antibiotic Drug Consumption in Young Children: An Interrupted Time-Series Analysis
Dana Danino et al.
CLINICAL INFECTIOUS DISEASES (2021)
The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy
Lindsay R. Grant et al.
EXPERT REVIEW OF VACCINES (2021)
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age
Nicola P. Klein et al.
VACCINE (2021)
Estimating Serotype-specific Efficacy of Pneumococcal Conjugate Vaccines Using Hierarchical Models
Joshua L. Warren et al.
EPIDEMIOLOGY (2020)
A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus
Feroze Ganaie et al.
MBIO (2020)
Diabetes mellitus as a vaccine-effect modifier: a review
Thomas Verstraeten et al.
EXPERT REVIEW OF VACCINES (2020)
A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands
Bradford D. Gessner et al.
VACCINE (2019)
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands
Bradford D. Gessner et al.
VACCINE (2019)
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults
Allison Thompson et al.
VACCINE (2019)
Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis
John M. McLaughlin et al.
VACCINE (2019)
Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader
Natalie Groves et al.
GENES (2019)
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
John M. McLaughlin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Accuracy of composite diagnostic standards for pneumococcal pneumonia in vaccine trials
M. Suzuki et al.
EPIDEMIOLOGY AND INFECTION (2018)
Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study
Shamez N. Ladhani et al.
LANCET INFECTIOUS DISEASES (2018)
How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015
Pernille Jorgensen et al.
VACCINE (2018)
Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults
Jose A. Suaya et al.
VACCINE (2018)
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Kathleen L. Dooling et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects
Keith P. Klugman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Improving Assessments of Population-level Vaccine Impact
Christian A. W. Bruhn et al.
EPIDEMIOLOGY (2017)
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls
Jennifer R. Verani et al.
VACCINE (2017)
Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly
Susanne M. Huijts et al.
VACCINE (2017)
Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
Chris Webber et al.
VACCINE (2017)
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
Anna M. M. van Deursen et al.
CLINICAL INFECTIOUS DISEASES (2017)
The public health value of vaccines beyond efficacy: methods, measures and outcomes
A. Wilder-Smith et al.
BMC MEDICINE (2017)
Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies
Marc Lipsitch et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2016)
The scrutiny of identifying community-acquired pneumonia episodes quantified bias in absolute effect estimation in a population-based pneumococcal vaccination trial
Cornelis H. van Werkhoven et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate
Bradford D. Gessner et al.
VACCINE (2016)
The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly
Cornelis H. van Werkhoven et al.
CLINICAL INFECTIOUS DISEASES (2015)
Pneumococcal Capsules and Their Types: Past, Present, and Future
K. Aaron Geno et al.
CLINICAL MICROBIOLOGY REVIEWS (2015)
The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
Cornelis H. van Werkhoven et al.
FUTURE MICROBIOLOGY (2015)
Vaccine against Pneumococcal Pneumonia in Adults
Andrew W. Swartz
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
M. J. M. Bonten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines
Tamara Pilishvili et al.
VACCINE (2015)
Use of vaccines as probes to define disease burden
Daniel R. Feikin et al.
LANCET (2014)
Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy
Bradford D. Gessner et al.
VACCINE (2014)
Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions
Kimberly M. Shea et al.
OPEN FORUM INFECTIOUS DISEASES (2014)
Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia
Susanne M. Huijts et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Vaccines for preventing pneumococcal infection in adults
Sarah Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine
Michael W. Pride et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
Albert Jan van Hoek et al.
JOURNAL OF INFECTION (2012)
Efficacy of pneumococcal vaccination in adults: a meta-analysis
Anke Huss et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
分享论文
